The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00861809
First received: February 26, 2009
Last updated: August 2, 2012
Last verified: July 2012
  Purpose

The purpose of this study is to assess the pharmacodynamic effects (gastric emptying), safety, tolerability, and pharmacokinetics of single doses of GSK962040 in Type 1 diabetic patients with gastroparesis.


Condition Intervention Phase
Gastroparesis
Drug: GSK962040 25 mg
Drug: Placebo
Drug: GSK962040 50 mg
Drug: GSK962040 1250 mg
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and PK of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Type 1 Diabetic Male and Female Patients With Gastroparesis

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Gastric emptying, as measured by the 13C octanoic acid breath test (Gastric half emptying time (t1/2b), Duration of the lag time (tlag), Gastric evacuation coefficient (GEC)) [ Time Frame: 1.5 h post dose to 5.5 h post dose ] [ Designated as safety issue: No ]
  • Safety and tolerability of GSK962040 (Change from baseline and number of patients outside the normal range for blood pressure, heart rate, 12-lead ECG parameters) [ Time Frame: 2 h post dose ] [ Designated as safety issue: Yes ]
  • Pharmacokinetic parameters of GSK962040: Cmax, Tmax, AUC(0-t), AUC(0-inf) for single-dose, CL/F, V/F, and, if possible, half-life [ Time Frame: 24 h post dose ] [ Designated as safety issue: No ]
  • Safety and tolerability of GSK962040 (Adverse events) [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
  • Safety and tolerability of GSK962040 (Change from baseline in clinical chemistry and hematology parameters) [ Time Frame: 24 h post dose ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Bowel movement parameters (Time to first bowel movement after first dose, Bowel movement count, Stool consistency (Bristol Stool Form scale)) [ Time Frame: 24 h post dose ] [ Designated as safety issue: No ]
  • PK/PD relationship of PP, plasma glucagon, GLP-1, and ghrelin after a single dose of GSK962040. [ Time Frame: 0-6 h post dose ] [ Designated as safety issue: No ]
  • Plasma glucose [ Time Frame: 24 h post dose ] [ Designated as safety issue: No ]
  • Food intake [ Time Frame: 24 h post dose ] [ Designated as safety issue: No ]

Enrollment: 11
Study Start Date: June 2009
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1 Period 1
All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
Drug: GSK962040 25 mg
25 mg
Drug: Placebo
placebo comparator
Drug: GSK962040 50 mg
50 mg
Drug: GSK962040 1250 mg
125 mg
Experimental: Cohort 1 Period 2
All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
Drug: GSK962040 25 mg
25 mg
Drug: Placebo
placebo comparator
Drug: GSK962040 50 mg
50 mg
Drug: GSK962040 1250 mg
125 mg
Experimental: Cohort 1 Period 3
All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
Drug: GSK962040 25 mg
25 mg
Drug: Placebo
placebo comparator
Drug: GSK962040 50 mg
50 mg
Drug: GSK962040 1250 mg
125 mg

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Controlled Type 1 Diabetes Mellitus (glucose < 250 mg/dL) with onset < 30 years of age.
  • Male or female between 18 and 70 years of age, inclusive.
  • Patient has documented diagnosis of moderate to severe gastroparesis (> 30% at 2 h as determined by scintigraphy; or t1/2b > 109 min as determined by 13C-octanoic acid breath test). All of the following apply:
  • Confirmed delayed gastric emptying (properly conducted gastric emptying assessments within last 6 months acceptable) AND a minimum 3 month history of relevant symptoms for gastroparesis (e.g., chronic postprandial fullness, postprandial nausea, vomiting)
  • A female patient is eligible to participate if she is of:
  • Non-childbearing potential
  • Child-bearing potential and agrees to use contraception for at least 4 days following the last dose of study medication.
  • Male patients must agree to use contraception from the time of the first dose of study medication through at least 4 days after the last dose of study medication.
  • Body weight ≤110 kg and BMI < 32.0 kg/m2 (inclusive).
  • Patient has never had a gastrectomy, nor major gastric surgical procedure or any evidence of bowel obstruction within the previous 12 months
  • Dosage of any concomitant medications has been stable for at least 3 weeks, except for routine adjustments in daily insulin treatments
  • HbA1c level is ≤ 10.0%
  • Calculated creatinine clearance > or equal to 50 ml/min
  • QTcB or QTcF < 450 msec or QTc<480msec in patients with Bundle Branch Block based on single or average QTc value of triplicate values obtained over a brief recording period.
  • AST, ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria:

  • Patient has acute severe gastroenteritis
  • Patient has a gastric pacemaker
  • Patient is on chronic parenteral feeding
  • Patient has daily persistent severe vomiting
  • Patient has pronounced dehydration
  • Patient has had clinical diabetic ketoacidosis in last 4 weeks
  • Patient has a history of eating disorders (anorexia nervosa, binge eating, bulimia)
  • Use of medications potentially influencing upper gastrointestinal motility or appetite within one week of the study (e.g., prokinetic drugs, macrolide antibiotics (erythromycin))
  • Patient is taking opiates.
  • Use of prohibited medications listed in Section 9.2 within the restricted timeframe relative to the first dose of study medication.
  • History or presence of clinically significant gastro-intestinal, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
  • Presence of thyroid dysfunction (NOTE: patients with abnormal TSH at screening/baseline are not eligible. Patients with a history of hypothyroidism on a stable dose of thyroid replacement therapy are eligible to participate in the study).
  • The patient has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • Pregnant females as determined by positive serum or urine hCG test (from the first urine of the day) at screening or prior to dosing.
  • Lactating or pregnant females.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Patients deemed unable to comply with the procedures outlined in the protocol may be excluded at the Investigator's discretion.
  • For male volunteers: An unwillingness of the male patient to comply with the contraception requirements listed in Section 8.1, from the time of the first dose of study medication until at least 4 days following administration of the last dose of study medication.
  • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00861809

Locations
Belgium
GSK Investigational Site
Leuven, Belgium, 3000
Sweden
GSK Investigational Site
Stockholm, Sweden, SE-171 76
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00861809     History of Changes
Other Study ID Numbers: 111809
Study First Received: February 26, 2009
Last Updated: August 2, 2012
Health Authority: Sweden: Regional Ethical Review Board
Belgium: Institutional Review Board
Belgium: Federal Agency for Medicines and Health Products, FAMHP
Sweden: Medical Products Agency

Keywords provided by GlaxoSmithKline:
single dose
gut motility
Type I Diabetes Mellitus patients
tolerability
phase II
13C octanoic acid breath test
pharmacodynamics
gastric emtpying
pharmacokinetics

Additional relevant MeSH terms:
Gastroparesis
Stomach Diseases
Gastrointestinal Diseases
Digestive System Diseases
Paralysis
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on September 30, 2014